Kemwell Biopharma will be attending and exhibiting at the upcoming CBI Bio/Pharmaceutical Manufacturing conference in Philadelphia PA July 24-25.
Event: Bio/Pharmaceutical Manufacturing Outsourcing
With increased scrutiny on the bio/pharmaceutical industry for cost containment, it is more important than ever for companies to learn the most efficient and productive ways to outsource manufacturing and manage costs. In this focused, interactive forum, bio/pharmaceutical executives come together with contract manufacturing organizations to discuss strategies for effective operations, quality oversight and risk mitigation. Join your colleagues to hear the latest regulatory trends, learn best sourcing practices and identify business opportunities in the outsourcing arena.
About Kemwell Biopharma: With manufacturing locations in India and Sweden, Kemwell offers CMC services ranging from Clinical (CTM) Manufacturing, Commercial Manufacturing, Formulation Development, Analytical Services, & Packaging/Storage/Distribution for solids, liquids, semi-solids, parenterals, & biopharmaceuticals.
Voted as the “Best CMO in India” by OPPI in 2010, Kemwell has been serving multinational pharma since 1980.
April 17th 2012
Kemwell announces the expansion of its new Pharmaceutical Development labs:
Kemwell Biopharma Pvt. Ltd., an India-based formulations contract manufacturer, has expanded its state-of-the-art pharmaceutical development labs in Bangalore, including a 7,500 sq. ft. cGMP pilot facility to support pharmaceutical projects from pre-formulation to finished products.
“We are seeing an increasing demand for contract development services in the global market. Kemwell has invested in a world-class facility with experienced scientists to meet the growing needs of its customers. With the new labs, Kemwell continues to build upon its ongoing commitment to be a high-quality one-stop shop service provider for its customers,” said Anurag Bagaria, Managing Director.
The 15,000 sq. ft. facility has capabilities to handle solids, injectables (large and small molecules), liquids and semi-solids dosage forms. Currently, the labs have 80 scientists with the ability to scale up to 150 scientists. Our scientists have extensive expertise in developing formulations for conventional and specialized dosage forms, including sustained release (SR) and modified release (MR) solids, liquids, and injectables.
Kemwell has the capability to offer customers pharmaceutical services that include pre-formulation, formulation development, analytical method development and validation, process optimization and scale-up, packaging development, pivotal batch manufacturing, stability batch manufacturing, stability studies, clinical batch manufacturing, labeling for blinded studies, preparation of placebo batches, tech transfer as well as commercial manufacturing. This enhanced facility coupled with our commercial manufacturing network on the same site, enables Kemwell to offer a wider scale of services for the development, testing and commercialization of large and small molecules. In Sweden, Kemwell also provides services for QP release. Says Anurag Bagaria, “Kemwell’s sites in India and Sweden can work in harmony to provide the customer with the best solution from both worlds”.
About Kemwell Biopharma Pvt. Ltd:
Bangalore-based Kemwell Biopharma Pvt. Ltd. (www.kemwellbiopharma.com) is a leading provider of formulations contract development and manufacturing services for multinational pharmaceutical companies for 30 years. From facilities in India & Sweden, Kemwell manufactures tablets, capsules, liquid orals, external drops, ointments, gels and creams. Kemwell’s customers include 5 of the top 10 pharmaceutical companies in the world. With 100% commitment to pure play contract manufacturing, Kemwell has no branded products of its own in the market, thereby avoiding any conflict of interest with its customers. Kemwell has recently built a new state-of-the art biologics manufacturing facility in Bangalore in collaboration with Boehringer Ingelheim to offer process development and cGMP manufacturing services for drug substance and drug product.
Kemwell Biopharma will be attending Interphex 2012 May 1-3, in New York City. Come see us at booth 1354
INTERPHEX – bringing together key pharma and biotech professionals with suppliers to create innovative solutions at the industry’s largest event. The conference will cover Regulatory, Product Development, Facility & Process Design, Manufacturing, Packaging, and Supply Chain.
Kemwell Biopharma is contract provider of CMC services to the pharmaceutical industry. With manufacturing locations in Bangalore India, and Uppsala Sweden, Kemwell offers services ranging from Clinical (CTM) Manufacturing, Commercial Manufacturing, Formulation Development, Analytical Development, & Packaging/Storage/Distribution.
Voted as the “Best Contract Manufacturer in India” by OPPI in 2010, Kemwell has been serving multinational pharma since 1980 & offers the entire value chain of CMC services from Phase 1 to Commercial, for Solids, Liquids, Semi-Solids, Biologics, & Injectables.
Kemwell Biopharma will be attending the annual DCAT meeting in NYC.
Drug, Chemical & Associated Technologies Association, Inc. (DCAT) is the premier business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical, and related industries.
Christian Ahlmark, Director of Corporate Development will be attending on behalf of Kemwell. email@example.com
With manufacturing locations in India and Sweden, Kemwell offers CMC services ranging from Clinical (CTM) Manufacturing, Commercial Manufacturing, Formulation Development, Analytical Services, & Packaging/Storage/Distribution for solids, liquids, semi-solids, parenterals, & biopharmaceuticals.
Voted as the “Best Contract Manufacturer in India” by OPPI in 2010, Kemwell has been serving multinational pharma since 1980.